ISB News

TCGA, ISB Researchers Identify Potential Drug Targets for Leading Form of Deadly Liver Cancer

June 19, 2017

Researchers in ISB’s Shmulevich Lab and their colleagues in The Cancer Genome Atlas Research Network performed the first large-scale, multi-platform analysis of hepatocellular carcinoma, the predominant form of liver cancer. Study was published on June 15, 2017, in the journal Cell.

3 Bullets:

  • Liver cancer is the second most common cause of death from cancer worldwide.
  • ISB researchers and colleagues from The Cancer Genome Atlas Research Network performed the first large-scale, multi-platform analysis of hepatocellular carcinoma, the predominant form of liver cancer.
  • Such integrated analyses enabled the identification of potential therapeutic targets and facilitated biological insights that would not have been possible otherwise.

READ THE SUMMARY AND PAPER

 

Recent Articles

  • Timing is Everything: ISB Study Finds Link Between Bowel Movement Frequency and Overall Health

    Everybody poops, but not every day. An ISB-led research team examined the clinical, lifestyle, and multi-omic data of more than 1,400 healthy adults. How often people poop, they found, can have a large influence on one’s physiology and health.

  • Wei Wei, PhD

    Dr. Wei Wei Promoted to Associate Professor

    Wei Wei, PhD – an accomplished cancer researcher with expertise in biotechnology and cancer systems biology – has been promoted to ISB associate professor. The Wei Lab focuses on understanding how cancer cells adapt to therapeutic treatment to foster therapy resistance by coordinating their internal molecular machinery and how these adaptive changes evolve within diverse tumors influenced by the tumor microenvironment. 

  • Drs. Nitin Baliga and James Park

    How Glioblastoma Resists Treatment – and Ways to Prevent It

    Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.